Revenio: Take advantage of temporary weakness
The Q3 result was better than our expectations thanks to strong profitability under the circumstances, but we lowered our forecasts for the coming years as the company's gave more precise market assessments. The result will turn positive next year but will be more concentrated towards the end of the year. The big picture has not changed, the company's competitiveness is intact, and a quality company deserves a higher valuation (2024e adj. EV/EBIT 17x) as growth accelerates again.
Login required
This content is only available for logged in users
Revenio Group
Revenio is a medical technology company. Within the Group, there is research and development of pressure measurement technology that is used in the treatment of a number of diseases such as glaucoma, osteoporosis, skin cancer, and asthma. Operations are held worldwide and are run via most subsidiaries, each with a business focus. The company's head office is located in Vantaa.
Read more on company pageKey Estimate Figures27.10.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 97.0 | 95.2 | 101.6 |
growth-% | 23.10 % | -1.82 % | 6.65 % |
EBIT (adj.) | 30.9 | 27.5 | 30.0 |
EBIT-% (adj.) | 31.84 % | 28.92 % | 29.52 % |
EPS (adj.) | 0.86 | 0.78 | 0.87 |
Dividend | 0.36 | 0.38 | 0.41 |
Dividend % | 0.93 % | 1.39 % | 1.50 % |
P/E (adj.) | 44.64 | 35.48 | 31.64 |
EV/EBITDA | 30.64 | 24.56 | 21.50 |